Skip to main content

Cambrex invests in Sweden

Small molecule CDMO Cambrex is to spend $3.6 million to increase flexible drug substance manufacturing capacity by 6 m3 (25%) at Karlskoga, Sweden, in response to growing demand for commercial-scale API manufacturing. Engineering work has already commenced and should be completed by November.

WeylChem invests at Lamotte

Following on from recent investments at other group sites, WeylChem has announced plans to spend over €5 million to upgrade its speciality chemicals assets at Lamotte in France.
Subscribe to investment

 

 

 

AMRI banner advert